Tomonori Ishii

5.7k total citations · 1 hit paper
153 papers, 2.8k citations indexed

About

Tomonori Ishii is a scholar working on Rheumatology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tomonori Ishii has authored 153 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Rheumatology, 45 papers in Immunology and 41 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tomonori Ishii's work include Systemic Lupus Erythematosus Research (44 papers), Vasculitis and related conditions (31 papers) and T-cell and B-cell Immunology (14 papers). Tomonori Ishii is often cited by papers focused on Systemic Lupus Erythematosus Research (44 papers), Vasculitis and related conditions (31 papers) and T-cell and B-cell Immunology (14 papers). Tomonori Ishii collaborates with scholars based in Japan, United States and United Kingdom. Tomonori Ishii's co-authors include Hideo Harigae, Hiroshi Fujii, Yasuhiko Munakata, Takeshi Sasaki, Tsuyoshi Shirai, Yasuhiko Hirabayashi, Ryu Watanabe, Chikao Morimoto, Yuko Shirota and Yoshiya Tanaka and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Tomonori Ishii

148 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis

2025 16 citations Tomonori Ishii et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tomonori Ishii Japan	28	864	747	690	640	428	153	2.8k
Nicole Fabien France	35	764 0.9×	894 1.2×	388 0.6×	740 1.2×	425 1.0×	146	3.7k
Hajime Yoshifuji Japan	26	1.2k 1.4×	743 1.0×	579 0.8×	415 0.6×	234 0.5×	146	2.4k
Nathalie Bardin France	30	552 0.6×	747 1.0×	274 0.4×	1.1k 1.8×	355 0.8×	111	2.8k
Stefan Kuchen Switzerland	24	855 1.0×	1.7k 2.2×	528 0.8×	903 1.4×	416 1.0×	35	3.2k
Wayel H. Abdulahad Netherlands	39	1.3k 1.5×	1.9k 2.6×	1.7k 2.4×	667 1.0×	430 1.0×	128	4.3k
Koichiro Ohmura Japan	35	1.8k 2.1×	1.9k 2.6×	441 0.6×	872 1.4×	514 1.2×	170	4.3k
Shigeto Tohma Japan	33	1.6k 1.9×	968 1.3×	409 0.6×	578 0.9×	354 0.8×	182	3.5k
Jordi Yagüe Spain	41	851 1.0×	2.4k 3.2×	558 0.8×	2.3k 3.6×	684 1.6×	146	5.8k
Stamatis‐Nick C. Liossis Greece	34	1.5k 1.7×	1.9k 2.6×	700 1.0×	802 1.3×	416 1.0×	100	4.0k
Christopher Sjöwall Sweden	38	2.2k 2.6×	2.1k 2.8×	199 0.3×	612 1.0×	287 0.7×	175	3.8k

Countries citing papers authored by Tomonori Ishii

Since Specialization

Citations

This map shows the geographic impact of Tomonori Ishii's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomonori Ishii with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomonori Ishii more than expected).

Fields of papers citing papers by Tomonori Ishii

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomonori Ishii. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomonori Ishii. The network helps show where Tomonori Ishii may publish in the future.

Co-authorship network of co-authors of Tomonori Ishii

This figure shows the co-authorship network connecting the top 25 collaborators of Tomonori Ishii. A scholar is included among the top collaborators of Tomonori Ishii based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomonori Ishii. Tomonori Ishii is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tanaka, Yoshiya, Tatsuya Atsumi, Tomoya Miyamura, et al.. (2025). Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 study. Modern Rheumatology. 35(3). 470–477. 1 indexed citations

Satoh, Taijyu, Saori Yamamoto, Yusuke Yamada, et al.. (2025). Long‐Term Prognostic and Hemodynamic Outcomes of Intensive Immunosuppressive Therapy in Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. International Journal of Rheumatic Diseases. 28(10). e70431–e70431.

Ichikawa, Satoshi, Koichi Onodera, Yoko Okitsu, et al.. (2025). Methotrexate-associated Angioimmunoblastic T-cell Lymphoma Presenting with Acute Kidney Injury. Internal Medicine. 65(1). 167–172.

Tanaka, Yoshiya, Tatsuya Atsumi, Masato Okada, et al.. (2025). Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial. Modern Rheumatology. 35(3). 458–469. 1 indexed citations

Izumiya, Yasuhiro, Toru Kubo, Jin Endo, et al.. (2024). Transthyretin Amyloid Cardiomyopathy: Literature Review and Red-Flag Symptom Clusters for Each Cardiology Specialty. ESC Heart Failure. 12(2). 955–967. 2 indexed citations

Tanaka, Yoshiya, et al.. (2024). Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus. RMD Open. 10(3). e004701–e004701. 9 indexed citations

Hatano, Ryo, Hayato Nakamura, Ayako Yamamoto, et al.. (2024). An abnormal increase in CD26(−)CD28(−) cytotoxic effector CD4 and CD8 T cell populations in patients with systemic lupus erythematosus. International Immunology. 37(3). 153–172.

Sugihara, Takahiko, Hajime Yoshifuji, Haruhito A. Uchida, et al.. (2023). Establishing clinical remission criteria for giant cell arteritis: Results of a Delphi exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis. Modern Rheumatology. 34(3). 568–575. 2 indexed citations

Yamazaki, Tomohide, Hiroko Sato, Tsuyoshi Shirai, et al.. (2023). Phospholipase D4 as a signature of toll-like receptor 7 or 9 signaling is expressed on blastic T-bet + B cells in systemic lupus erythematosus. Arthritis Research & Therapy. 25(1). 200–200. 7 indexed citations

10.

Waddington‐Cruz, Márcia, Yoshiki Sekijima, Haruki Koike, et al.. (2023). Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal. Orphanet Journal of Rare Diseases. 18(1). 323–323. 6 indexed citations

11.

Ishii, Tomonori, et al.. (2023). Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: A 48-week interim analysis of the MARS study. Modern Rheumatology. 34(5). 978–987. 9 indexed citations

12.

Sato, Hiroko, et al.. (2022). Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis. Clinical and Experimental Rheumatology. 41(2). 291–300. 21 indexed citations

13.

Shirai, Tsuyoshi, Yoichi Kakuta, Hiroko Sato, et al.. (2022). Development of severe colitis in Takayasu arteritis treated with tocilizumab. Clinical Rheumatology. 41(6). 1911–1918. 9 indexed citations

14.

Shirai, Tsuyoshi, Tomonori Ishii, Yuko Shirota, et al.. (2020). Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis. Nature Communications. 11(1). 1253–1253. 53 indexed citations

15.

Ogata, Atsushi, et al.. (2017). A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period. Modern Rheumatology. 28(1). 76–84. 15 indexed citations

16.

Nakamura, Kyohei, M. NAKAYAMA, Mitsuko Kawano, et al.. (2013). NK-cell fratricide: Dynamic crosstalk between NK and cancer cells. OncoImmunology. 2(11). e26529–e26529. 8 indexed citations

17.

Hirabayashi, Yasuhiko, et al.. (2010). The Endoplasmic Reticulum Stress-Inducible Protein, Herp, Is a Potential Triggering Antigen for Anti-DNA Response. The Journal of Immunology. 184(6). 3276–3283. 16 indexed citations

18.

Ishii, Tomonori, Kei Ohnuma, Akikazu Murakami, et al.. (2003). SS-A/Ro52, an Autoantigen Involved in CD28-Mediated IL-2 Production. The Journal of Immunology. 170(7). 3653–3661. 44 indexed citations

19.

Ohnuma, Kei, Yasuhiko Munakata, Tomonori Ishii, et al.. (2001). Soluble CD26/Dipeptidyl Peptidase IV Induces T Cell Proliferation Through CD86 Up-Regulation on APCs. The Journal of Immunology. 167(12). 6745–6755. 51 indexed citations

20.

Suzuki, Yoko, Tadao Funato, Yasuhiko Munakata, et al.. (2000). Chemically Modified Ribozyme to V Gene Inhibits Anti-DNA Production and the Formation of Immune Deposits Caused by Lupus Lymphocytes. The Journal of Immunology. 165(10). 5900–5905. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact